Merrimack Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Gary Crocker
Chief executive officer
US$134.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.6yrs |
| CEO ownership | 0.9% |
| Management average tenure | no data |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment
Dec 02Merrimack Pharmaceuticals reports Q3 results
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$134k | n/a | -US$1m |
| Sep 30 2023 | n/a | n/a | -US$1m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$105k | n/a | -US$2m |
| Sep 30 2022 | n/a | n/a | -US$2m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | US$105k | n/a | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$4m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$90k | n/a | -US$3m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$11m |
| Dec 31 2019 | US$95k | n/a | -US$21m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$45m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$123k | n/a | -US$61m |
| Sep 30 2018 | n/a | n/a | -US$60m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$64m |
| Dec 31 2017 | US$175k | US$31k | -US$75m |
Compensation vs Market: Gary's total compensation ($USD134.23K) is below average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
CEO
Gary Crocker (71 yo)
7.6yrs
Tenure
US$134,234
Compensation
Mr. Gary L. Crocker, MBA, has been President (Principal Executive Officer) and Treasurer (Principal Financial and Accounting Officer) of Merrimack Pharmaceuticals, Inc. since June 28, 2019. He is Chief Exe...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 20.3yrs | US$134.23k | 0.93% $ 2.0m | |
| Co-Founder & Independent Director | 9.3yrs | US$123.45k | 0.25% $ 543.9k | |
| Member of Scientific Advisory Board | 6.3yrs | US$39.38k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Director | 4.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Director | 1.9yrs | US$125.45k | 0.029% $ 61.3k |
6.3yrs
Average Tenure
60yo
Average Age
Experienced Board: MACK's board of directors are considered experienced (6.3 years average tenure).